Loading
A phase 1/2 trial of Fludarabine, Cyclophosphamide in melanoma and uveal melanoma, run by Beijing Biotech, now recruiting.
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma is a phase 1/2 interventional study registered as NCT07627698 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-06-14. Interventions recorded: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide. Conditions listed: Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.